Breast Cancer

Compounds Exhibit Synergistic Activity with Herceptin and Taxotere

Published in Women's Health Weekly, January 11th, 2001

New research reported December 8, 2000, at the annual San Antonio Breast Cancer meeting showed that exisulind (Aptosyn^TM) and CP461 inhibit cell growth and trigger apoptosis in human breast cancer cell lines, including cells lacking HER-2/neu or estrogen receptors.

The data were presented by Drs. Li Liu and W. Joseph Thompson from Cell Pathways and their collaborators, Drs. Mark Pegram and Dennis Slamon at the University of California, Los Angeles, Jonsson Cancer Center

The researchers also reported that in breast cancer lines that overexpress HER-2/neu or estrogen receptors, exisulind and CP461 each demonstrate synergistic anticancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry